• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Editor’s Choice

Editor's Choice

Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome

December 2, 2021 Microbiome Times

Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]

Editor's Choice

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development

December 1, 2021 Luis Gosálbez

Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]

Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

November 23, 2021 Aaron B Cowley and Nicole O'Brien

Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]

Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

November 16, 2021 Travis Whitfill

  The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]

Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

September 30, 2021 Microbiome Times

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The […]

Editor's Choice

Microbes turn back the clock as research discovers their potential to reverse aging in the brain

August 31, 2021 Microbiome Times

Research from APC Microbiome Ireland (APC) at University College Cork (UCC) published in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function […]

Editor's Choice

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

July 2, 2021 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]

Editor's Choice

Ferring and Rebiotix Present Landmark Phase 3 Data

May 24, 2021 Microbiome Times

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]

Editor's Choice

The surprising evolutionary history of our oral bacteria

May 12, 2021 Microbiome Times

Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species – our microbiome. These microbes play key roles in human health, but little is known about their evolution. […]

Editor's Choice

Fecal transplant turns cancer immunotherapy non-responders into responders

February 10, 2021 Microbiome Times

Fecal transplant changes the gut microbiome, turning cancer immunotherapy non-responders into responders. Video Credits: UNIVERSITY OF PITTSBURGH   Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut […]

Editor's Choice

Why microbiota samples should be collected in all clinical trials?

January 26, 2021 Isabelle de Cremoux

In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing interest towards our microbiome research-focused Health for Life […]

Posts navigation

« 1 … 5 6 7 … 14 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter